title: Population pharmacokinetics of native Escherichia coli asparaginase.
abstract: The main aim of this analysis was to characterize the population pharmacokinetics of native Escherichia coli asparaginase (ASNase medac) in pediatric patients with previously untreated acute lymphoblastic leukemia. Secondary objective was to give further evidence for bioequivalence between ASNase medac and a new recombinant ASNase preparation. The authors reanalyzed 233 plasma samples from 16 children treated according to the DCOG-ALL 10 protocol (5000 U/m(2) ASNase medac) using NONMEM. Subsequently, assessment of bioequivalence was performed by including the preparation as a categorical covariate into the PopPK model when analyzing data of both preparations (480 samples, 32 children). A linear 2-compartment model with first-order elimination sufficiently described ASNase medac pharmacokinetics. The parameters found were as follows: total body clearance 0.13 L/h ± 12.4% per 1.73 m(2), volume of distribution in the central compartment 4.11 L ± 12.3% per 70 kg, volume of distribution in the peripheral compartment 1.63 L per 70 kg and intercompartmental clearance 0.106 L/h (mean ± interindividual variability). A visual predictive check procedure and simulation of different dosages ASNase medac administered in the ALL-BFM protocol indicated adequate model performance. Assessment of bioequivalence provided a difference of about 14% in clearance of both preparations being too small to be considered as clinically relevant. A population pharmacokinetic model of ASNase medac in pediatric patients with previously untreated acute lymphoblastic leukemia was established. The model was able to describe asparaginase activity of different dosages in the ALL-BFM protocol and provides further evidence for bioequivalence between ASNase medac and a new recombinant asparaginase preparation.
authors.affiliation: Department of Pharmaceutical and Medical Chemistry-Clinical Pharmacy, University of Münster, Münster, Germany. sborg_01@unimuenster.de
authors.forename: Stephan
authors.initials: S
authors.lastname: Borghorst
authors.forename: Rob
authors.initials: R
authors.lastname: Pieters
authors.forename: Hans-Juergen
authors.initials: HJ
authors.lastname: Kuehnel
authors.forename: Joachim
authors.initials: J
authors.lastname: Boos
authors.forename: Georg
authors.initials: G
authors.lastname: Hempel
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002648:Child; D004311:Double-Blind Method; D004926:Escherichia coli / Q000201:enzymology*; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D015203:Reproducibility of Results
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D001215:Asparaginase